Michael  Catelani net worth and biography

Michael Catelani Biography and Net Worth

President, COO & CFO of Anixa Biosciences

Mr. Catelani is a seasoned executive with over 30 years of finance and operations management experience. He currently serves as President, Chief Operation Officer & Chief Financial Officer of Anixa Biosciences. Previously, Mike cofounded Tacere Therapeutics, Inc., a privately held biotech company, and served as its Chairman, President & Chief Financial Officer until its sale. Prior to Tacere, Mike served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, an Australian Stock Exchange-listed biotech company. Mike was Vice President and Chief Financial Officer at Axon Instruments, a leading designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research. Axon was a U.S. corporation publicly traded on the Australian Stock Exchange. Previously, he was the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed company. Mike has also worked with several early-stage start-ups in a variety of industries, including biotechnology, cleantech  and retail, in both advisory and management roles and has served as a contract CFO for a number of established businesses in the biotech field. Mike began his professional career at Ernst & Young and is a CPA (Inactive). He received his BS degree in business administration, with a concentration in accountancy from Sacramento State University and earned his MBA from the University of California, Davis.

What is Michael Catelani's net worth?

The estimated net worth of Michael Catelani is at least $160.20 thousand as of January 15th, 2025. Mr. Catelani owns 44,500 shares of Anixa Biosciences stock worth more than $160,200 as of August 28th. This net worth approximation does not reflect any other assets that Mr. Catelani may own. Learn More about Michael Catelani's net worth.

How do I contact Michael Catelani?

The corporate mailing address for Mr. Catelani and other Anixa Biosciences executives is 3150 ALMADEN EXPRESSWAY SUITE 250, SAN JOSE CA, 95118. Anixa Biosciences can also be reached via phone at (408) 708-9808 and via email at [email protected]. Learn More on Michael Catelani's contact information.

Has Michael Catelani been buying or selling shares of Anixa Biosciences?

Michael Catelani has not been actively trading shares of Anixa Biosciences over the course of the past ninety days. Most recently, on Wednesday, January 15th, Michael Catelani bought 9,289 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $2.15 per share, with a total value of $19,971.35. Following the completion of the transaction, the chief financial officer now directly owns 44,500 shares of the company's stock, valued at $95,675. Learn More on Michael Catelani's trading history.

Who are Anixa Biosciences' active insiders?

Anixa Biosciences' insider roster includes Arnold Baskies (Director), Michael Catelani (President, COO & CFO), Emily Gottschalk (Director), Amit Kumar (CEO), and Lewis Titterton, Jr. (Director). Learn More on Anixa Biosciences' active insiders.

Are insiders buying or selling shares of Anixa Biosciences?

In the last year, Anixa Biosciences insiders bought shares 9 times. They purchased a total of 60,024 shares worth more than $179,370.60. The most recent insider tranaction occured on July, 31st when CEO Amit Kumar bought 5,000 shares worth more than $17,350.00. Insiders at Anixa Biosciences own 26.4% of the company. Learn More about insider trades at Anixa Biosciences.

Information on this page was last updated on 7/31/2026.

Michael Catelani Insider Trading History at Anixa Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/15/2025Buy9,289$2.15$19,971.3544,500View SEC Filing Icon  
6/7/2024Buy6,250$2.40$15,000.0035,211View SEC Filing Icon  
7/20/2023Buy5,500$3.64$20,020.0026,655View SEC Filing Icon  
4/20/2022Buy2,509$2.53$6,347.7712,635View SEC Filing Icon  
See Full Table

Michael Catelani Buying and Selling Activity at Anixa Biosciences

This chart shows Michael Catelani's buying and selling at Anixa Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anixa Biosciences Company Overview

Anixa Biosciences logo
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Read More

Today's Range

Now: $3.60
Low: $3.52
High: $3.68

50 Day Range

MA: $3.30
Low: $2.62
High: $3.75

2 Week Range

Now: $3.60
Low: $2.32
High: $5.46

Volume

337,331 shs

Average Volume

212,886 shs

Market Capitalization

$122.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55